A Phase 3 interventional study of Etoricoxib 60 mg and Etoricoxib 90 mg in Arthritis, Rheumatoid, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2-part (6 weeks duration for each part), randomized, double-blind, placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
This study's enrollment of 1,404 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
Drug: Etoricoxib 60 mg · Drug: Placebo to Etoricoxib 60 mg
The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
Drug: Etoricoxib 60 mg · Drug: Placebo to Etoricoxib 60 mg
The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
Drug: Etoricoxib 90 mg · Drug: Placebo to Etoricoxib 90 mg
The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
Drug: Placebo to Etoricoxib 60 mg · Drug: Placebo to Etoricoxib 90 mg
One tablet orally once daily for 6 weeks.
Also known as: MK-0663
One tablet orally once daily for 6 weeks.
Also known as: MK-0663
One tablet orally once daily for 6 weeks.
One tablet orally once daily for 6 weeks
Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)
Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.
Time frame: Baseline and Week 6
Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)
A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.
Time frame: Baseline and Week 6
Percentage of Participants Who Experienced at Least One Adverse Event (AE)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Time frame: Up to 112 days
Percentage of Participants Who Discontinued Study Drug Due to an AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Time frame: Up to Week 12
Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)
Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.
Time frame: Baseline and Week 6
Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg)
A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.
Time frame: Baseline and Week 6
Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1
A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with \<50% improvement from baseline in PGAP \[VAS\] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.
Time frame: Week 6 and Week 10 to Week 12
| Milestone | Etoricoxib 60 mg | Etoricoxib 90 mg | Etoricoxib 60 mg/Etoricoxib 60 mg | Etoricoxib 60/Etoricoxib 90mg | Placebo |
|---|---|---|---|---|---|
| Started | 818 | 468 | 0 | 0 | 118 |
| Completed | 719 | 413 | 0 | 0 | 96 |
| Not completed | 99 | 55 | 0 | 0 | 22 |
| Withdrew: Withdrawal by subject | 11 | 10 | 0 | 0 | 0 |
| Withdrew: Technical problem | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 10 | 5 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 3 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 37 | 12 | 0 | 0 | 17 |
| Withdrew: Adverse event | 26 | 24 | 0 | 0 | 4 |
| Milestone | Etoricoxib 60 mg | Etoricoxib 90 mg | Etoricoxib 60 mg/Etoricoxib 60 mg | Etoricoxib 60/Etoricoxib 90mg | Placebo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 350 | 363 | 0 |
| Completed | 0 | 0 | 334 | 343 | 0 |
| Not completed | 0 | 0 | 16 | 20 | 0 |
| Withdrew: Adverse event | 0 | 0 | 6 | 7 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 5 | 7 | 0 |
Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.
| Scores on a scale | Etoricoxib 60 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo) | -1.39 (-1.48 to -1.30) | -1.37 (-1.48 to -1.26) | -1.10 (-1.29 to -0.90) |
A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The primary objectives of the study compared the efficacy of etoricoxib (90 mg, 60 mg) to placebo in Part 1 of this study so data for only these 3 arms are displayed.
| Scores on a scale | Etoricoxib 60 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo) | -28.25 (-30.05 to -26.44) | -30.96 (-33.13 to -28.79) | -20.26 (-24.04 to -16.48) |
Disease Activity Score Using C-Reactive Protein \[DAS28-CRP\] (0 - 10 Range). The DAS28-CRP index is a composite score of weighted components including tender joint counts of 28, swollen joint counts of 28, patient global assessment of disease activity, and C-reactive protein (CRP). For each observation (Baseline, Week 2, 4, 6, 10, 12), components were combined into a single DAS28-CRP score using the following algorithm: 0.56\*square root (sqrt) (tender joint count \[28\])+0.28\*sqrt(swollen joint count \[28\] )+0.36\* ln(crp+1) + 0.014\* Patient Global Assessment of Disease Activity + 0.96. The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.
| Scores on a scale | Etoricoxib 60 mg | Etoricoxib 90 mg |
|---|---|---|
| Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg) | -1.39 (-1.48 to -1.30) | -1.37 (-1.48 to -1.26) |
A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). The key secondary objectives compared the relative efficacy between etoricoxib 90 mg and 60 mg in Part 1 of this study so data for only these 2 arms are displayed.
| Scores on a scale | Etoricoxib 60 mg | Etoricoxib 90 mg |
|---|---|---|
| Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib 90 mg vs. Etoricoxib 60 mg) | -28.25 (-30.05 to -26.44) | -30.96 (-33.13 to -28.79) |
A participant overall assessment of pain on a visual analog scale (VAS) was assessed with a question concerning the amount of pain due to arthritis during the past 48 hours. Pain was assessed on an 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm). In those participants who were considered inadequate responders to etoricoxib 60 mg in Part 1 (defined as a participant with \<50% improvement from baseline in PGAP \[VAS\] at Week 6), the incremental benefit of increasing the etoricoxib dose from 60 mg (in Part 1) to 90 mg (in Part 2) compared to remaining on 60 mg in Part 2 was evaluated via average change from Week 6 over Weeks 10 and 12 in Patient Global Assessment of Pain score. Therefore, data for only these 2 arms are displayed.
| Scores on a scale | Etoricoxib 60 mg/Etoricoxib 60 mg | Etoricoxib 60 mg/Etoricoxib 90 mg |
|---|---|---|
| Average Change From Week 6 in Patient Global Assessment of Pain Over Weeks 10 and 12 in Part 2 Among Pain Inadequate Responders From Part 1 | -11.96 (-14.96 to -8.97) | -10.35 (-13.32 to -7.39) |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
| Percentage of participants | Etoricoxib 60 mg - Part 1 | Etoricoxib 90 mg - Part 1 | Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2 | Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2 | Placebo - Part 1 |
|---|---|---|---|---|---|
| Percentage of Participants Who Experienced at Least One Adverse Event (AE) | 30.3 | 36.0 | 19.1 | 24.5 | 25.4 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
| Percentage of participants | Etoricoxib 60 mg - Part 1 | Etoricoxib 90 mg - Part 1 | Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2 | Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2 | Placebo - Part 1 |
|---|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Drug Due to an AE | 3.3 | 5.1 | 1.4 | 1.9 | 3.4 |
Collected over Up to 112 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etoricoxib 60 mg - Part 1 | — | 7/819 (0.9%) | 25/819 (3.1%) |
| Etoricoxib 90 mg - Part 1 | — | 2/467 (0.4%) | 17/467 (3.6%) |
| Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2 | — | 4/350 (1.1%) | 6/350 (1.7%) |
| Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2 | — | 5/363 (1.4%) | 6/363 (1.7%) |
| Placebo - Part 1 | — | 0/118 (0%) | 6/118 (5.1%) |
| Event | Etoricoxib 60 mg - Part 1 | Etoricoxib 90 mg - Part 1 | Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2 | Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2 | Placebo - Part 1 |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/819 | 0/467 | 1/350 | 0/363 | 0/118 |
| Haemorrhoidal haemorrhageGastrointestinal disorders | 0/819 | 0/467 | 1/350 | 0/363 | 0/118 |
| Non-cardiac chest painGeneral disorders | 2/819 | 0/467 | 1/350 | 0/363 | 0/118 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/819 | 0/467 | 1/350 | 0/363 | 0/118 |
| Acute myocardial infarctionCardiac disorders | 0/819 | 0/467 | 0/350 | 1/363 | 0/118 |
| Coronary artery diseaseCardiac disorders | 0/819 | 0/467 | 0/350 | 1/363 | 0/118 |
| Gastroenteritis viralInfections and infestations | 0/819 | 0/467 | 0/350 | 1/363 | 0/118 |
| PyomyositisInfections and infestations | 0/819 | 0/467 | 0/350 | 1/363 | 0/118 |
| Hip fractureInjury, poisoning and procedural complications | 0/819 | 0/467 | 0/350 | 1/363 | 0/118 |
| Cerebrovascular accidentNervous system disorders | 0/819 | 0/467 | 0/350 | 1/363 | 0/118 |
| Event | Etoricoxib 60 mg - Part 1 | Etoricoxib 90 mg - Part 1 | Etoricoxib 60mg/Etoricoxib 60mg - Part 1/2 | Etoricoxib 60mg/Etoricoxib 90mg - Part 1/2 | Placebo - Part 1 |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 25/819 | 17/467 | 6/350 | 6/363 | 6/118 |
| Age, Continuous(Years) | Etoricoxib 60 mg | Etoricoxib 90 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 53.8 ± 11.9 | 54.0 ± 12.3 | 53.6 ± 11.0 | 53.8 ± 12.0 |
| Sex: Female, Male(Participants) | Etoricoxib 60 mg | Etoricoxib 90 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 677 | 395 | 100 | 1172 |
| Male | 141 | 73 | 18 | 232 |
| Disease Activity Score using C reactive protein (DAS28-CRP)(Scores on a scale) | Etoricoxib 60 mg | Etoricoxib 90 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 5.64 ± 0.99 | 5.62 ± 1.00 | 5.65 ± 1.12 | 5.63 ± 1.00 |
| Patient Global Assessment of Pain(Scores on a scale) | Etoricoxib 60 mg | Etoricoxib 90 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 70.84 ± 15.50 | 70.58 ± 15.02 | 74.08 ± 14.23 | 71.02 ± 15.24 |
No study locations are listed for this record.
Plan to share: No
Ran from Sep 2010 to primary completion in Jun 2014, 44 months.
Results were first posted in May 2015, 11 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 44 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etoricoxib